<DOC>
	<DOCNO>NCT02516410</DOCNO>
	<brief_summary>Study evaluate efficacy VX-661 combination ivacaftor Week 12 subject cystic fibrosis ( CF ) heterozygous F508del mutation CF transmembrane conductance regulator ( CFTR ) gene second CFTR mutation likely respond VX-661 and/or ivacaftor therapy ( F508del/not responsive [ NR ] ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety VX-661 Combination With Ivacaftor Subjects Aged 12 Years Older With Cystic Fibrosis , Heterozygous F508del-CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF define sweat chloride value ≥60 mmol/L quantitative pilocarpine iontophoresis Heterozygous F508delCFTR mutation second CFTR mutation likely respond VX661 and/or ivacaftor therapy FEV1 ≥40 % ≤90 % predict normal age , sex , height Screening Visit . History comorbidity , opinion investigator , might confound result study pose additional risk administer study drug subject An acute upper low respiratory infection , pulmonary exacerbation , change therapy ( include antibiotic ) pulmonary disease within 28 day Day 1 ( first dose study drug ) . History solid organ hematological transplantation . Ongoing prior participation investigational drug study use commercially available CFTR modulator within 30 day screen . Pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>